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Objective: Tumor-stroma ratio (TSR) has been identified as a new 
and practicable prognostic histological characteristic of solid tumors. 
The aim of this study was to evaluate the prognostic value of TSR in 
resected esophageal squamous cell carcinoma (ESCC).
Methods: A total of 95 patients who underwent esophagectomy for 
ESCC were included in this study. TSR was assessed visually on the 
hematoxylin-eosin–stained tissue sections of surgical specimens by 
two independent observers. Patients with more than 50% intratumor 
stroma were quantified as the stroma-rich group and those with less 
than 50% as the stroma-poor group.
Results: No significant differences were observed in patient, 
tumor, and treatment characteristics between the stroma-rich and 
stroma-poor groups. The 3-year overall survival and disease-free 
survival rates were 64% and 57%, respectively, in the stroma-poor 
group, and 23% and 23%, respectively, in the stroma-rich group. 
Both 3-year overall and disease-free survival rates in the stroma-
poor group were significantly better than those in the stroma-rich 
group (p < 0.01). In a multivariate analysis, TSR was identified as a 
highly significant prognostic factor for 3-year overall survival (haz-
ard ratio 3.450; p = 0.001) and 3-year disease-free survival (hazard 
ratio 2.995; p = 0.001), independent of pTNM stage and radicality 
of the primary tumor.
Conclusion: Stroma-rich tumors were associated with poor progno-
sis and an increased risk of relapse, which may serve as a new prog-
nostic histological characteristic in ESCC. TSR is simple and quick 
to determine, is reproducible, and could be easily incorporated in 
routine histological evaluation.
Key Words: Squamous cell carcinoma, Esophageal neoplasms, 
Survival, Tumor-stroma ratio
(J Thorac Oncol. 2012;7: 1457–1461)
Esophageal carcinoma is the eighth most common cancer and the sixth leading cause of cancer death in the world.1 
There are two major histological types of esophageal carci-
noma: esophageal squamous cell carcinoma (ESCC) and 
adenocarcinoma with considerably varied epidemiological 
features. In China and other East Asian countries, more than 
90% of cases are ESCC, whereas adenocarcinoma is more 
common in the United States and European countries.
Tumors are complex tissue composed of carcinoma 
cells and surrounding stroma. The prognostic factors of ESCC 
include tumor location, depth of tumor invasion, number of 
involved lymph nodes, histological grade, and pTNM stage. 
To date, it is increasingly acknowledged that tumor stroma is 
indispensable for cancer initiation, progression, and metasta-
sis, and the stromal elements of tumor hold prognostic poten-
tial. Recently, tumor-stroma ratio (TSR) was proved to be a 
new prognostic factor in esophageal adenocarcinoma, early 
breast carcinoma, and colon carcinoma.2–4 To our knowledge, 
the prognostic value of TSR remained to be explored for 
ESCC. The objective of this study was to evaluate the prog-
nostic value of TSR in ESCC and its relationship with other 
prognostic factors.
PATIENTS AND METHODS
Patients and Tissue Samples
From the database of the Qilu Hospital of Shandong 
University, we selected all patients with ESCC who underwent 
resection with curative intent at the Department of Thoracic 
Surgery of the Qilu Hospital from 1 January to 31 December 
2007. Patients treated with neoadjuvant therapy, which could 
interfere with the evaluation of TSR were excluded, as were 
patients who died within 30 days after surgery. Patient, tumor, 
and treatment characteristics were retrieved from the Medical 
Records Room. Both original pathological reports and hema-
toxylin and eosin (HE)–stained sections from the primary 
tumor were retrieved from the Department of Pathology. All 
patients signed informed consent to this study, and the proto-
col was approved by the Ethics Committee of Qilu Hospital of 
Shandong University.
Histopathological Protocol
The 5-µm HE-stained sections from the primary tumor 
were routinely analyzed on microscopic examination. In case 
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of tumor heterogeneity, stroma-rich areas were considered to 
be of worse prognostic value and therefore deemed decisive.5 
In general, areas rich in stroma were found near the site of 
deepest microscopic infiltration. The surrounding stromal tis-
sue not containing tumor cells was considered not to be con-
nected with the tumor. Using a 4× microscope objective (40 × 
total magnification), we selected the most invasive tumor area 
for further evaluation. Subsequently, microscopical fields, 
where both stroma and tumor were present, and tumor cells 
were visualized on all sides and were scored with a 10× objec-
tive (100 × total magnification). The assessment was done on 
the basis of the analysis of at least one microscopic field. The 
estimate was then recorded as the TSR. With this protocol, 
tumor sections were independently assessed by two investiga-
tors. A third pathologist’s decision was decisive when the two 
observers disagreed. A 50% cutoff value was taken as previ-
ously determined in colon cancer, which was also confirmed 
in esophageal adenocarcinoma.3 TSR was defined as stroma 
poor (the proportion of stroma <50%) or stroma rich (the pro-
portion of stroma ≥50%). Tumor node metastasis staging was 
done according to the American Joint Committee on Cancer 
Cancer Staging Manual (7th ed, 2010).
Follow Up
Follow-up data were collected until death or March 
2011. All patients had a regular follow-up schedule including 
a complete history and physical examination every 3 months 
during the first 2 years after surgery and every 6 months 
thereafter. Routine radiological examinations were performed 
when necessary.
Statistical Analysis
Differences in patient, tumor, and treatment characteris-
tics were assessed using the Mann–Whitney test for continuous 
variables and the χ2 test for categorical variables. The Cohen’s 
κ coefficient was used to analyze the variability between the 
two investigators. The Kaplan–Meier method and log-rank test 
were used for analysis and comparison of survival curves. For 
the analysis of 3-year overall survival, events were defined as 
death from any cause. For the analysis of 3-year disease-free 
survival, events were defined as first loco-regional or distant 
tumor relapse or death from any cause. The Cox proportional 
hazards model was used to determine the hazard ratio (HR) 
of variables on 3-year overall survival and 3-year disease-free 
survival in univariate and multivariate analysis. The results are 
given as HRs with their 95% confidence interval (CI). p values 
less than 0.05 were considered statistically significant. Data 
were analyzed using statistical package SPSS version 17.0 
(SPSS Inc., Chicago, IL).
RESULTS
Clinicopathological Features
Ninety-five patients (82 men and 13 women) were 
included in this study. The median age of the patients was 60 
(range, 42–77) years at the date of surgery. The median fol-
low-up time was 40 (4–50) months. Clinicopathological and 
treatment characteristics of patients are shown in Table 1.
Tumor-Stroma Ratio in ESCC
With 4× and 10× objectives, routine HE–stained sec-
tions from the primary tumors were analyzed for the pres-
ence of stromal involvement. TSR was assessed on one 
section derived from the most invasive part of the tumor 
(Fig. 1). Estimation of the TSR was performed successfully 
in all tumors. Assessed by two independent researchers, 65 
tumors were stroma poor and 30 were stroma rich. Cohen’s κ 
TABLE 1.  Patient, Tumor and Treatment Characteristics 




(N = 95) (n = 65) (n = 30)
No. % No. % No. %
Sex
 Men 82 86.3 58 89.2 24 80.0
0.224
 Women 13 13.7 7 10.8 6 20.0
Median age (range) 60.0 (42–77) 60.0 (42–77) 60.5 (45–77) 0.128
Median tumor length 
in mm (range)
38 (9–130) 40 (9–85) 38 (9–130) 0.926
Tumor location
 Upper 10 10.5 7 10.8 3 10.0
0.387 Middle 56 59.0 41 63.0 15 50.0
 Low 29 30.5 17 26.2 12 40.0
pT status
 pT1 10 10.5 9 13.8 1 3.3
0.060 pT2 18 19.0 15 23.1 3 10.0
 pT3/4 67 70.5 41 63.1 26 86.7
pN status
 pN0 56 58.9 38 58.5 18 60.0
0.964
 pN1 25 26.3 19 27.7 8 23.3
 pN2 11 11.6 7 10.8 4 13.3
 pN3 3 3.2 2 3.0 1 3.4
Lymph node ratio
 <0.2 73 76.8 53 81.5 20 66.7
0.110
 ≥0.2 22 23.2 12 18.5 10 33.3
pTNM stage
 I 13 13.7 11 16.9 2 6.7
0.394 II 48 50.5 32 49.2 16 53.3
 III 34 35.8 22 33.8 12 40.0
Differentiation grade
 Well 28 29.5 20 30.8 8 26.7
0.918 Moderate 40 42.1 27 41.5 13 43.3
 Poor 27 28.4 18 27.7 9 30.0
Radicality
 R0 92 96.8 63 96.9 29 96.7
0.212 R1 2 2.1 2 3.1 0 0
 R2 1 1.1 0 0 1 3.3
Adjuvant therapy
 No 47 49.5 35 53.8 12 40.0
0.210
 Yes 48 50.5 30 46.2 18 60.0
pT, pathological tumor stage; pN, pathological node stage; pTNM, tumor node 
metastasis.
ap < 0.05 was considered significant.
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coefficient revealed an almost perfect agreement between two 
researchers (κ = 0.84).
Correlation of TSR With Other 
Prognostic Factors
Table 1 shows patient, tumor, and treatment characteris-
tics for the stroma-rich and the stroma-poor groups. There were 
no significant differences between the two groups. Follow up 
was complete. The 3-year overall survival rate and disease-free 
survival rate were 64% and 57%, respectively, in the stroma-
poor group and 23% and 23%, respectively, in the stroma-rich 
group. Median overall survival for patients in the stroma-poor 
group was 39 months (95% CI 36–43 months) compared with 
24 months (95% CI 18–29 months) for patients in the stroma-
rich group. Survival curves are shown in Fig. 2. The differ-
ence of survival curves between the two groups remained 
statistically significant. In the Cox univariate and multivariate 
analysis of 3-year survival, the HR of TSR was 3.548 (95% 
CI 1.977–6.365; p = 0.001) and 3.450 (95% CI 1.913–6.222; 
p = 0.001), respectively. In the Cox univariate model, TSR, 
lymph node status, lymph node ratio, pTNM stage, depth 
of tumor invasion (T3/4), and radicality of resection were 
significantly related to 3-year overall survival. In the Cox uni-
variate and multivariate analysis of disease-free survival, the 
HRs for TSR were 2.635 (95% CI 1.526–4.548; p = 0.001) 
and 2.995 (95% CI 1.706–5.260; p = 0.001), respectively. 
TSR was also an independent prognostic variable for 3-year 
disease-free survival and node status and radicality of resec-
tion (Tables 2 and 3).
DISCUSSION
The present investigation shows that TSR is a new inde-
pendent prognostic factor for ESCC. Stroma-rich tumors were 
associated with poor prognosis and an increased risk of relapse.
The use of TSR as a prognostic factor has been 
introduced by previous studies.2–4 After analysis of 122 
patients with stage I to III colon carcinoma, Mesker et al.4 
found that patients with TSR less than 50% showed significant 
worse overall and disease-free survivals, which suggested that 
FIGURE 1. Hematoxylin and eosin stained 5 µm sections of eso-
phageal squmaous cell carcinoma (original magnification ×100). 
A, Example of stroma-rich (stroma ratio ≥ 50%). B, Example of 
stroma-poor (stroma ratio < 50%).
FIGURE 2.  Kaplan-Meier curves for survival of all 95 patients 
with esophageal squamous cell carcinoma (stroma poor ver-
sus stroma rich). Both 3-year overall survival (A) and disease-
free survival (B) between two groups remained statistically 
significant.
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TSR could serve as an independent parameter for confident 
prediction of clinical outcome in early-stage colon cancer. 
Recently, TSR was also confirmed to be a new and practicable 
prognostic tumor characteristic in esophageal adenocarcinoma 
and early breast cancer.2–4 Our hypothesis was that TSR might 
also be an important prognostic parameter for ESCC. The 
optimal threshold level of TSR was determined on the basis 
of a maximum discriminating power for overall survival and 
disease-free survival. The 50% cutoff value was the most 
representative. In the study, we found that 3-year survival rate 
and disease-free survival rate were 64% and 57%, respectively, 
in the stroma-poor group, and 23% and 23%, respectively, in 
the stroma-rich group. TSR was of prognostic value by both 
univariate and multiverate analysis.
Many prognostic factors have been found for ESCC, 
such as the number and the ratio positive lymph nodes,6 pTNM 
stage, tumor location, depth of tumor invasion, and histologi-
cal grade. All these factors have been included in our analysis. 
In the study, we found that lymph node status, positive lymph 
node ratio, pTNM stage, depth of tumor invasion (T3/4), and 
radicality of resection were significantly related to 3-year 
overall survival in univariate analysis, and pTNM stage and 
radicality of resection were also independent prognostic fac-
tors in multivariate analysis. For 3-year disease-free survival, 
radicality of resection and pN3 status (metastasis in seven or 
more regional lymph nodes) were independent prognostic fac-
tors through multivariate analysis. Our results were similar to 
those of previous studies.7
Tumor tissue is composed of both carcinoma cells and 
stromal cells recruited from normal tissue. In normal tissue, 
the stroma may actually act as a barrier in tumorigenesis 
by constraining tumor cell proliferation. In tumor tissue, 
however, stromal components—the main part of tumor 
microenvironment—could facilitate the process of tumor 
progression.8 The mechanism underlying tumor-promoting 
effect of stroma is still not fully understood, which may 
be associated with an increased number of fibroblasts 
(higher stroma ratio), reconstruction of the extracellular 
matrix, increased microvessel and microlymphatic density, 
recruitment of inflammatory cells etc. Recently, the so-called 
cancer-associated fibroblasts (CAFs) composed of the major 
TABLE 2. Cox Univariate Analysis for 3-Year Survival in 95 
Patients of Esophageal Squamous Cell Carcinoma
Univariate Analysisa
3-Yr Overall Survival 3-Yr Disease-Free 
Survival
HR 95% CI pb HR 95% CI pb
TSR 0.001 0.001
 Stroma-poor 1.000 Ref. — 1.000 Ref. —
 Stroma-rich 3.548 1.977–6.365 0.001 2.635 1.526–4.548 0.001
Differentiation 
grade 0.565 0.469
 Well 1.000 Ref. — 1.000 Ref. —
 Moderate 1.444 0.696–2.996 0.324 1.263 0.640–2.496 0.501
 Poor 1.450 0.658–3.195 0.356 1.573 0.763–3.243 0.220
Tumor location 0.362 0.365
 Upper 1.000 Ref. — 1.000 Ref. —
 Middle 0.632 0.261–1.529 0.309 0.780 0.326–1.865 0.577
 Low 0.490 0.184–1.307 0.490 0.537 0.205–1.408 0.206
pT status 0.054 0.362
 pT1 1.000 Ref. — 1.000 Ref. —
 pT2 4.254 0.523–34.581 0.176 1.104 0.361–3.377 0.862
 pT3/4 7.741 1.061–56.452 0.044 1.676 0.658–4.269 0.279
pN status 0.044 0.145
 pN0 1.000 Ref. — 1.000 Ref. —
 pN1 1.771 0.899–3.488 0.098 1.316 0.692–2.501 0.403
 pN2 2.522 1.115–5.702 0.026 1.771 0.804–3.901 0.156
 PN3 3.501 1.043–11.752 0.043 3.439 1.038–11.389 0.043
Lymph node 
ratio 0.025 0.183
 <0.2 1.000 Ref. — 1.000 Ref. —
 ≥0.2 2.029 1.094–3.761 0.025 1.501 0.825–2.731 0.183
pTNM stage 0.015 0.118
 I 1.000 Ref. — 1.000 Ref. —
 II 7.981 1.075–59.258 0.042 1.471 0.599–3.607 0.400
 III 13.404 1.807–99.436 0.011 2.313 0.934–5.728 0.070
Radicality 0.048 0.068
 R0 1.000 Ref. — 1.000 Ref. —
 R1 3.424 0.813–14.432 0.094 2.392 0.575–9.955 0.231
 R2 7.154 0.933–54.842 0.058 8.350 1.076–64.766 0.042
Adjuvant 
therapy 0.454 0.254
 No 1.000 Ref. — 1.000 Ref. —
 Yes 1.248 0.699–2.231 0.454 1.374 0.796–2.372 0.254
pT, pathological tumor stage; pN, pathological node stage; pTNM: tumor node 
metastasis; TSR, tumor-stroma ratio; HR, hazard ratio; CI, confidence interval; Ref., 
reference.
aAnalysis was performed using the Cox proportion hazard model.
bp <0.05 was considered significant (indicated in bold).
TABLE 3. Multivariate Cox Analysis for 3-Yr Survival in 95 
Patients of Esophageal Squamous Cell Carcinoma
Multivariate Analysisa
3-Yr Overall Survival 3-Yr Disease-Free Survival
HR 95% CI pb HR 95% CI pb
pT status 
(T3/4)
2.727 0.330–22.553 0.352 0.988 0.319–3.059 0.983
pN status 
(N3)
2.715 0.693–10.630 0.152 4.652 1.393–15.541 0.012
TSR (Stroma-
rich)
3.450 1.913–6.222 0.001 2.995 1.706–5.260 0.001
Lymph node 
ratio ≥0.2
1.280 0.542–3.024 0.573 0.794 0.333–1.895 0.603
pTNM 
stage(III)
11.560 1.556–85.873 0.017 1.990 0.596–6.647 0.264
Radicality 
(R1-2)
4.738 1.395–16.090 0.013 4.125 1.244–13.679 0.020
pT, pathological tumor stage; pN, pathological node stage; pTNM, tumor node 
metastasis; TSR, tumor-stroma ratio; HR, hazard ratio; CI, confidence interval.
aAnalysis was performed using the Cox proportion hazard model.
bp < 0.05 was considered significant.
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cellular components of tumor stroma were found to have a 
predominant role in tumor growth and progression. Quiescent 
fibroblasts activated in tumor stroma are key regulators of 
the paracrine signaling between stroma and cancer cells.9 
CAFs, consisting of both fibroblasts and myofibroblasts, 
are frequently observed in the stroma of human carcinoma 
and secrete a variety of soluble factors such as transforming 
growth factor beta 1 (TGF-β1), stromal cell-derived factor 
1 and other soluble factors secreted by CAFs, that act in a 
paracrine manner and affect not only cancer cells but also 
other cell types present in the stroma.10 CAFs could produce 
various growth factors, cytokines, and extracellular matrix 
proteins to promote angiogenesis, which is essential for tumor 
growth and progression.11 Tumor immunity is also mediated 
via cytokines secreted by CAFs. Balsamo et al.12 found 
that CAFs could modulate immune cell type and antitumor 
activity. The CAFs play an important role in some aspects of 
cancer biology including transformation, progression, tumor 
growth, and drug resistance,13 and their presence in large 
numbers is often associated with the development of high-
grade malignancies and poor prognosis.14
Our results indicated that increased amount of stromal 
proportion in ESCC can be connected with a poor prognosis 
independent of other prognostic factors. In addition, TSR can 
be easily assessed and performed during routine pathological 
examination.15
Although our study population was homogenous, the 
study has its shortcomings. This was a retrospective study 
with a relatively small sample size and the follow-up time is 
short. It is of greater value to conduct a prospective biopsy 
study with a larger sample size in the future.
In conclusion, our findings indicate that TSR is a new 
prognostic factor for ESCC. TSR can be determined easily 
during routine pathological examination on HE-stained 
sections of the resected tumor. Carcinoma has long been 
viewed as a disease of transformed epithelial cells, and 
treatment strategies focused only on tumor cells. The 
study of tumor stroma has opened great opportunities for 
future cancer therapy. Targeting components of the tumor 
microenvironment have great potential in the clinical 
practice, particularly when used in combination with other 
therapeutic agents.
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